ederal court this past spring gave the Food and Drug Administration six months to prove it was making progress on a promised safety review of the abortion pill mifepristone, in Louisiana’s litigation challenging the Biden administration’s relaxed prescribing conditions, or the judge might reimpose politically popular restrictions including in-person dispensing.
That deadline came Wednesday, a month before midterm elections projected to rip the House if not the Senate away from Republicans, and pro-life groups crucial to mitigating Democratic inroads are crying foul at the Justice Department’s status report to U.S. District Judge David Joseph, which finally describes the review’s sources and timeline after nearly a year of vagaries.